The American Society for Clinical Oncology (ASCO) has featured an Australian trial of neoadjuvant therapy in melanoma as a part of its 2020 Advance of the Year in cancer. In its annual review, ASCO selected Refinement of Surgical Treatment of Cancer as the 2020 Advance of the Year, saying that studies such as the NeoCombi ...
Australian oncology research is ASCO Advance of the Year
By Michael Woodhead
11 Feb 2020